BostonGene

BostonGene wins “Cancer Immunology Solution of the Year” from BioTech Breakthrough for our AI-driven, blood-based immune system profiling platform! Read more: https://lnkd.in/eRhdaGxr

We are excited to announce a collaboration with BeiGene to advance biomarker discovery in mantle cell lymphoma. This collaboration will leverage BostonGene's comprehensive AI platform and molecular profiling to identify biomarkers associated with disease response and resistance. Read more: https://lnkd.in/eKWtgEca “At BostonGene, we are dedicated to unraveling the complexity of hematologic malignancies through data-driven molecular and clinical analysis. Our work with BeiGene will facilitate the identification of clinically actionable biomarkers, with the goal of advancing personalized therapeutic approaches and improving outcomes for MCL patients.” - Nathan Fowler, MD, Chief Medical Officer at BostonGene

BostonGene contributed to a white paper with Friends of Cancer Research entitled “Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications.” The paper highlights key considerations and strategic recommendations to improve the development of companion diagnostic tests for rare biomarkers and conditions to enhance patient outcomes. “The process outlined in this white paper establishes new benchmarks for developing companion diagnostics for rare indications. BostonGene is honored to contribute to this forward-thinking initiative, which addresses significant gaps in current practices and ensures patients with rare conditions receive equitable access to cutting-edge care.” Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene Read more: https://lnkd.in/e7PCyp-p

🏆 Pharmaceutical Technology Excellence Awards 2024 – Winners Announced! The Pharmaceutical Technology Excellence Awards Winners have been announced! To see the full list you can download the full 50+ page report from the following link: Download Awards Report - https://lnkd.in/d2Rd-Vqw A big congratulations to our featured winners - IMAGE ANALYSIS GROUP, Pharma Solutions at IFF, Syngene International Limited, PCI Pharma Services, EMIS, BostonGene, Medidata Solutions, West Pharmaceutical Services, Botanical Solution, SecureCHEK® AI and Catalent Pharma Solutions #pharma #clinicaltrials #biopharma #pharmaawards #biotech

BostonGene's Chief Scientific Officer, Joe Lennerz, MD, PhD, will discuss the importance of high-quality data, ground truth and integrating new diagnostic technologies into patient care at the @CancerResrch meeting, Advancing the Future of Diagnostics and Regulatory Innovations, on Feb 4 in DC! #AI #CancerResearch #Diagnostics Read more: https://lnkd.in/eEF8Rsn6

Join us next week at #FOG2025! Joe Lennerz, MD, PhD, BostonGene’s chief scientific officer, will deliver a presentation titled "Genomics at Machine Speed," highlighting the transformative role of machine-driven advancements in genomics and high-complexity testing in healthcare. Front Line Genomics Read more: https://lnkd.in/eEPckeMq

We are excited to collaborate with the Lombardi Comprehensive Cancer Center to explore novel #immunotherapy combinations in patients with gastrointestinal cancers and microscopic residual disease, using #immuneprofiling as an early relapse indicator to guide targeted therapies and improve survival rates. Read more: https://lnkd.in/e6UkaBiA

As we reflect on another meaningful year, we extend our heartfelt gratitude for your continued support, dedication and partnership. Wishing you a joyful holiday season and a prosperous 2025.

Stop by booth #1317 this week at #SABCS24 and learn more about how BostonGene's molecular profiling is transforming breast cancer treatment!

Join us this week at #SABCS24, where we will present research on transcriptomic classification, ADC target analysis, and ctDNA monitoring—driving advancements in precision oncology solutions to enable personalized treatment pathways for breast cancer patients. “We’re excited to present our research at the 2024 SABCS, underscoring BostonGene’s commitment to leveraging molecular profiling as a transformative tool in breast cancer treatment. Our findings in transcriptomic classification aim to pave the way for more effective treatment pathways, establishing new benchmarks for precision oncology.” - Nathan Fowler, MD, Chief Medical Officer, BostonGene Learn more: https://lnkd.in/eu4wDQkx